Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?

Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?

Objective. Interstitial lung disease (ILD) is rare, but it is one of the most frequent extra-articular manifestations and a relevant cause of morbidity and mortality in rheumatoid arthritis (RA). Over the past few years, Janus kinase inhibitors (JAKis) have been reported to have promising efficacy...

Full description

Saved in:
Bibliographic Details
Main Authors: Beatrice Maranini, Roberta Foti, Moustapha Taha, Veronica Venturelli, Andrea Lo Monaco, Marcello Govoni
Format: Article
Language:English
Published: PAGEPress Publications 2025-01-01
Series:Reumatismo
Subjects:
JAK inhibitors
interstitial lung disease
ILD
rheumatoid arthritis
RA
Online Access:https://www.reumatismo.org/reuma/article/view/1754
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.reumatismo.org/reuma/article/view/1754

Similar Items